CJC-1295.
4 vendors · $25–64

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29), developed by ConjuChem Biotechnologies in the mid-2000s. It is a tetrasubstituted form of GHRH(1-29) (Jetté et al., 2005). The name covers two chemically distinct forms.

A Phase II study in healthy adults (Teichman et al., 2006, J Clin Endocrinol Metab) reported that subcutaneous CJC-1295 with DAC produced sustained, dose-dependent increases in GH and IGF-I over several weeks. ConjuChem's Phase II programme in HIV-associated visceral adiposity (NCT00267527) was terminated in 2006 and development did not resume; the trials reviewed here did not evaluate body-composition or performance outcomes.

Neither form is approved as a medicine anywhere; both are sold research-use-only, and GHRH analogues are named on the WADA Prohibited List under S2, prohibited at all times for tested athletes. The DAC form carries a maleimidopropionyl linker that binds serum albumin, giving a reported half-life of 5.8–8.1 days (Teichman et al., 2006). The no-DAC form (Mod GRF 1-29) lacks the linker and is cleared far faster; we found no peer-reviewed half-life figure for it.